GlassScriptPhysician profile
Ralph Peterson
NPI 1851311104
$128,030.41
in general payments reported to CMS, 2019-2025
22 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $21K · 2021: $23K · 2022: $7,417 · 2023: $10K · 2024: $10K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $2,885 · Travel and Lodging: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,200.00 |
| Food and Beverage | $2,885.38 |
| Travel and Lodging | $1,129.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $122,052.61 | 2019-2025 | Epclusa, Vemlidy |
| Abbvie INC. | $2,759.80 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $858.08 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $637.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $515.35 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $268.30 | 2021-2023 | |
| Braintree Laboratories, INC. | $258.51 | 2021-2025 | Sutab, Suflave |
| Redhill Biopharma INC. | $148.43 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $148.42 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $72.95 | 2022-2023 | Ibsrela |
| Shionogi INC | $57.85 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $52.64 | 2021-2023 | Ocaliva |
| Genzyme Corporation | $42.30 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $30.18 | 2025 | Iqirvo |
| Viiv Healthcare Company | $29.05 | 2024 | Apretude |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $27.33 | 2023 | Linzess |
| Alfasigma USA, INC. | $18.71 | 2020 | |
| Pharmacosmos Therapeutics INC. | $16.67 | 2025 | Monoferric |
| Concordia Pharmaceuticals INC. | $11.86 | 2019 | |
| Napo Pharmaceuticals INC | $11.86 | 2019 | |
| Allergan, INC. | $11.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.